Specifically, for adenocarcinoma patients, our results indicate that PD-L1 expression levels and TP53 mutation status are significant factors affecting both OS and PFS, highlighting their potential relevance in predicting patient prognosis. This evidence concerns the gene TP53 and adenocarcinoma.